原发性肝癌的中西医研究进展
Research Progress in Traditional Chinese and Western Medicine for Primary Liver Cancer
DOI: 10.12677/acm.2024.1492494, PDF,   
作者: 廖 江:云南中医药大学第一临床学院,云南 昆明;王峻峰*:云南省第一人民医院肝胆胰外科,云南 昆明
关键词: 原发性肝癌中西医临床研究Primary Liver Cancer Traditional Chinese and Western Medicine Clinical Research
摘要: 目前原发性肝癌依旧是我国高发的恶性肿瘤之一,致死率也高居不下,对我国国民的身体健康存在着严重的威胁。近年来随着对肝恶性肿瘤的检查方式和治疗药物的不断更新发展,提高了我们对疾病的认知,进一步指导了肝恶性肿瘤的诊疗方案,也逐渐认识到治疗肝恶性肿瘤的多样化,从单纯的西医治疗慢慢加入中医辅助治疗从而过渡到中西医结合治疗,从局部治疗过渡到整体治疗,相辅相成地提高肝恶性肿瘤患者的治疗效果,改善患者的生存质量,延长患者的生存时间。
Abstract: *通讯作者。At present, primary liver cancer is still one of the most common malignant tumors in China, and the mortality rate is also high, which poses a serious threat to the health of Chinese people. In recent years, with the continuous updating and development of examination methods and therapeutic drugs for liver malignant tumors, our understanding of the disease has been improved, and the diagnosis and treatment plan of liver malignant tumors has been further guided, and the diversification of the treatment of liver malignant tumors has been gradually recognized. Starting from simple Western medicine treatment, gradually Joining traditional Chinese medicine as an adjuvant therapy to transition to integrated traditional Chinese and Western medicine treatment, and transitioning from local treatment to holistic treatment, complement each other to improve liver malignancy. The treatment effect of tumor patients improves their quality of life and prolongs their survival time.
文章引用:廖江, 王峻峰. 原发性肝癌的中西医研究进展[J]. 临床医学进展, 2024, 14(9): 535-539. https://doi.org/10.12677/acm.2024.1492494

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[3] Yang, J.D., Hainaut, P., Gores, G.J., Amadou, A., Plymoth, A. and Roberts, L.R. (2019) A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management. Nature Reviews Gastroenterology & Hepatology, 16, 589-604. [Google Scholar] [CrossRef] [PubMed]
[4] 夏永祥, 张峰, 李相成, 等. 原发性肝癌10966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17.
[5] 侯刘进, 赵红川. 肝切除术后肝功能不全诊治进展[J]. 肝胆外科杂志, 2015, 23(3): 235-237.
[6] 孙惠川, 沈英皓, 李小龙. 肝脏储备功能与肝癌术式选择[J]. 中国实用外科杂志, 2018, 38(4): 473-476.
[7] 陈斌, 胡志强. 原发性肝癌肝切除术后肝功能衰竭的风险因素分析[J]. 中华肝胆外科杂志, 2020 , 26(12): 881-885.
[8] 景霆. 行气散结化瘀方联合还原型谷胱甘肽治疗原发性肝癌术后临床研究[J]. 新中医, 2022, 54(17): 187-191.
[9] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版) [J]. 中华消化外科杂志, 2017, 16(7): 635-647.
[10] 晓明. 血清miRNAs检测在肝癌中的临床应用价值[J]. 河北医科大学学报, 2018, 39(4): 492-496.
[11] 吕平云. 丙型肝炎病毒感染引起醛缩酶Aldolase B下降的分子机制[D]: [硕士学位论文]. 北京: 中国科学院大学, 2016.
[12] 郑同宝. 扶正补虚方药治疗肝癌的实验及临床研究[D]: [博士学位论文]. 广州: 广州中医药大学, 2009: 18-20.
[13] 姚翔. 中医药治疗晚期原发性肝细胞肝癌疗效的Meta分析及原发性肝细胞肝癌伴门静脉癌栓的中医证候学分析[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2010: 23-25.
[14] 侯凤刚, 凌昌全. 原发性肝细胞肝癌中医辨证分型文献中专家观点统计分析[J]. 云南中医学院学报, 2003, 26(2): 6-7.